Navigation Links
Flu vaccines aimed at younger populations could break annual transmission cycle
Date:6/11/2013

h year. Historic efforts have been focused on people at higher risk of death and severe disease often the elderly, and those with chronic illness, weakened immune systems, health care workers or others.

With existing patterns of vaccine usage, the problem is enormous. Seasonal influenza in the U.S. results each year in an average of 36,000 deaths, more than 200,000 hospitalizations, an $87 billion economic burden, and millions of hours of lost time at school and work not to mention feeling sick and miserable.

The flu vaccine up until 2000 was only recommended for people over 65, Medlock said, and other age groups were added in the past decade as it became clear they also were at high risk of death or complications children from age six months to five years, and adults over 50. Just recently, age was taken completely out of the equation.

"Clearly we would want people at high medical risk to get a flu vaccine as long as it is abundant," Medlock said. "But what we're losing in our current approach is the understanding that most flu is transmitted by children and young adults. They don't as often die from it, but they are the ones who spread it to everyone else."

The population and disease transmission modeling done in the new study outlines this, and concluded that a 25-100 percent reduction in deaths from flu or its complications could be achieved if current flu vaccine usage were shifted to much more heavily include children and young adults, as well as those at high risk.

One obstacle, experts say, is the historic reluctance to add even more vaccines to those already received and often mandated for school-age children.

"A simple program we could consider in our K-12 schools would be to have the school nurse, or other local professional, give every child an annual flu shot, with the parents being informed about it in advance and having the option to decline," Medlock said.

"Vaccinating children could p
'/>"/>

Contact: Jan Medlock
jan.medlock@oregonstate.edu
541-737-6874
Oregon State University
Source:Eurekalert

Page: 1 2 3

Related biology news :

1. Cancer vaccines self-sabotage, channel immune attack to injection site
2. Novel aptamer boosts T cell-based immune response to therapeutic vaccines
3. Designer bacteria may lead to better vaccines
4. UMMS experts seek better flu vaccines
5. MVI and Inovio partner to develop malaria vaccines using innovative vaccine delivery tech
6. Mosquito virus could lead to new vaccines and drugs
7. Early activation of immune response could lead to better vaccines
8. Compound discovered that boosts effect of vaccines against HIV and flu
9. AAPS National Biotechnology Conference to highlight innovative vaccines
10. Researchers identify Achilles heel of dengue virus, target for future vaccines
11. EWiND facility aimed at improvements in wind energy
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/18/2014)... 17, 2014   News Highlights: ... to develop The Partners Data Lake, an agile ... Data Lake will allow researcher and clinicians to ... and the lives of patients , The ... activities across the Partners system, breaking down physical ...
(Date:11/18/2014)... NEW YORK , Nov. 18, 2014 /PRNewswire/ ... iris-based identity authentication solutions, and MorphoTrust USA ... solutions and services, today announced a strategic partnership ... across enterprise, motor vehicle administration (MVA), airport screening ... leader in identity-related solutions, MorphoTrust serves consumers through ...
(Date:11/12/2014)... , Nov. 12, 2014 Crossmatch™, a leading ... its U.are.U ® fingerprint readers have been deployed ... Central Mexico . The bakery chain ... eliminate payroll issues caused by employees clocking in for ... U.are.U fingerprint readers, Montparnasse relied on paper timecards and ...
Breaking Biology News(10 mins):Partners HealthCare and EMC Unite to Solve Health Care's Toughest Challenges Using Big Data 2Partners HealthCare and EMC Unite to Solve Health Care's Toughest Challenges Using Big Data 3Partners HealthCare and EMC Unite to Solve Health Care's Toughest Challenges Using Big Data 4Partners HealthCare and EMC Unite to Solve Health Care's Toughest Challenges Using Big Data 5EyeLock, MorphoTrust Form Strategic Partnership to Pursue Commercial Enterprise Deployments 2EyeLock, MorphoTrust Form Strategic Partnership to Pursue Commercial Enterprise Deployments 3Montparnasse Pasteleria Achieves Time and Attendance Transparency with Crossmatch U.are.U Fingerprint Readers 2
... - The meters-long, carnivorous "shrimp" from hell that once ruled the ... a real softy, it turns out. A new 3-D modeling of ... parts were not hard like teeth, but flexible, shows that the ... of trilobites and other such creatures of the early seas. ...
... Environmental Pollution " details successful experiments at the ... the abiotic (non-biological) transformation and absorption of four ... these estrogen hormones by more than 80 percent ... since it could point to inexpensive treatment technologies ...
... courses of antibiotics can leave normal gut bacteria harbouring ... treatment, say scientists writing in the latest issue of ... researchers believe that this reservoir increases the chances of ... survival and suggesting that the long-term effects of antibiotic ...
Cached Biology News:Earth's first great predator wasn't 2UC research: Rabbit's food brings luck in decreasing estrogen levels in wastewater 2UC research: Rabbit's food brings luck in decreasing estrogen levels in wastewater 3Antibiotics have long-term impacts on gut flora 2
(Date:11/26/2014)... -- Theravalues Corporation est fier d,annoncer le lancement ... salon Hi Europe 2014 (du 2 au 4 décembre ... Curcumine la plus biodisponible actuellement sur le marché, ... ingrédients approuvés par les règlements européens. ... la racine de curcuma ( Curcuma longa ) ...
(Date:11/26/2014)... -- Theravalues Corporation annuncia con orgoglio il lancio di ... Hi Europe 2014 (dal 2 al 4 dicembre, ... curcumina con la maggiore biodisponibilità di sempre, con una ... dalle norme europee. La curcumina è un ... Curcuma longa ) che è stata associata con attività ...
(Date:11/24/2014)... Nov. 24, 2014  IGI Laboratories, Inc. (NYSE MKT: ... specialty generic pharmaceutical company, today announced it has submitted ... U.S. Food and Drug Administration (FDA), which brings the ... seven, with eighteen submissions now pending at the FDA. ... CEO of the Company, commented, "Our team here at ...
(Date:11/24/2014)... 24, 2014  Last week, Representatives Gus ... (D-NC) took a bold bipartisan step on behalf ... OPEN Act. Original co-sponsors of the legislation include ... will incentivize drug makers and innovators to "repurpose" ... pediatric cancers, which opens the door to the ...
Breaking Biology Technology:La curcumine présentant la plus haute biodisponibilité bientôt en vente en Europe 2La curcumine présentant la plus haute biodisponibilité bientôt en vente en Europe 3La curcumina con la maggiore biodisponibilità di sempre farà il suo debutto in Europa 2La curcumina con la maggiore biodisponibilità di sempre farà il suo debutto in Europa 3IGI Laboratories, Inc. Announces ANDA Submission 2OPEN Act Introduced to Repurpose Drugs for Rare Diseases 2
... Ltd., a,privately-held drug development company with its headquarters ... new Phase IIa clinical testing of,ProtoCure(TM) emulsion cream, ... vehicle-controlled study is designed to,evaluate the tolerability, pharmacokinetics, ... of 18 subjects with mild to moderate plaque ...
... through non core divestitures - , - Caliper signs ... , - Non-cash restructuring and goodwill impairment charge ... Caliper Life Sciences, Inc. (Nasdaq: CALP ), today ... 2008. Fourth quarter revenues were $36.7 million, a decline ...
... Simcere Pharmaceutical Group,("Simcere" or the "Company,) (NYSE: ... pharmaceuticals and manufacturer of the patented,anti-cancer biotech product Endu ... and fiscal year ended December 31, 2008. , , ... revenue increased to RMB 466.9 million (US$68.4 million) for ...
Cached Biology Technology:BioCis Pharma Starts Phase IIa Trial in Psoriasis 2Caliper Life Sciences Reports Fourth Quarter and Full Year 2008 Results 2Caliper Life Sciences Reports Fourth Quarter and Full Year 2008 Results 3Caliper Life Sciences Reports Fourth Quarter and Full Year 2008 Results 4Caliper Life Sciences Reports Fourth Quarter and Full Year 2008 Results 5Caliper Life Sciences Reports Fourth Quarter and Full Year 2008 Results 6Caliper Life Sciences Reports Fourth Quarter and Full Year 2008 Results 7Caliper Life Sciences Reports Fourth Quarter and Full Year 2008 Results 8Caliper Life Sciences Reports Fourth Quarter and Full Year 2008 Results 9Caliper Life Sciences Reports Fourth Quarter and Full Year 2008 Results 10Caliper Life Sciences Reports Fourth Quarter and Full Year 2008 Results 11Caliper Life Sciences Reports Fourth Quarter and Full Year 2008 Results 12Caliper Life Sciences Reports Fourth Quarter and Full Year 2008 Results 13Caliper Life Sciences Reports Fourth Quarter and Full Year 2008 Results 14Simcere Pharmaceutical Group Reports Unaudited Fourth Quarter and Fiscal Year 2008 Results 2Simcere Pharmaceutical Group Reports Unaudited Fourth Quarter and Fiscal Year 2008 Results 3Simcere Pharmaceutical Group Reports Unaudited Fourth Quarter and Fiscal Year 2008 Results 4Simcere Pharmaceutical Group Reports Unaudited Fourth Quarter and Fiscal Year 2008 Results 5Simcere Pharmaceutical Group Reports Unaudited Fourth Quarter and Fiscal Year 2008 Results 6Simcere Pharmaceutical Group Reports Unaudited Fourth Quarter and Fiscal Year 2008 Results 7Simcere Pharmaceutical Group Reports Unaudited Fourth Quarter and Fiscal Year 2008 Results 8Simcere Pharmaceutical Group Reports Unaudited Fourth Quarter and Fiscal Year 2008 Results 9Simcere Pharmaceutical Group Reports Unaudited Fourth Quarter and Fiscal Year 2008 Results 10Simcere Pharmaceutical Group Reports Unaudited Fourth Quarter and Fiscal Year 2008 Results 11Simcere Pharmaceutical Group Reports Unaudited Fourth Quarter and Fiscal Year 2008 Results 12Simcere Pharmaceutical Group Reports Unaudited Fourth Quarter and Fiscal Year 2008 Results 13
Lingo-1 (K-13)...
HIF-1 beta (ARNT1) Purified Anti-Mouse, Anti-Rat, Anti-Human clone 29, Isotype Mouse IgG 1 , 50 µg Consult technical datasheet for details....
MOUSE ANTI PORCINE SLA 1:FITC Immunogen: Porcine peripheral blood mononuclear cells....
An excellent carbonyl-reactive FRET quencher paired with Trp or Tyr. Minimum Purity: 95%. Abs(max): ~350 nm; Em(max): none. Solvent System:DMSO or DMF....
Biology Products: